Indications and uses
temporarily relieves minor aches and pains due to: headache muscular aches minor pain of arthritis toothache backache the common cold menstrual cramps temporarily reduces fever
Ibuprofen
- Manufacturer
- Marc Glassman, Inc.
- Effective date
- 2021-03-31
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 22:48:04
Label at a glance#
ProductIbuprofen
Active ingredientIBUPROFEN
Label structure9 sections
Dosage and administration
do not take more than directed the smallest effective dose should be used do not take longer than 10 days, unless directed by a doctor (see Warnings ) adults and children 12 years and over take 1 caplet every 4 to 6 hours while symptoms persist if pain or fever does not respond to 1 caplet, 2 caplets may be used do not exceed 6 caplets in 24 hours, unless directed by a doctor children under 12 years ask a doctor
Storage and handling
store between 20°-25°C (68°-77°F) avoid excessive heat above 40°C (104°F) read all warnings and directions before use retain carton for complete product information
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active ingredient (in each caplet)
Purpose
Pain reliever/fever reducer
Uses
- temporarily relieves minor aches and pains due to:
- headache
- muscular aches
- minor pain of arthritis
- toothache
- backache
- the common cold
- menstrual cramps
- temporarily reduces fever
Warnings
Allergy alert
Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:
- hives
- facial swelling
- asthma (wheezing)
- shock
- skin reddening
- rash
- blisters
If an allergic reaction occurs, stop use and seek medical help right away.
Stomach bleeding warning
This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
- are age 60 or older
- have had stomach ulcers or bleeding problems
- take a blood thinning (anticoagulant) or steroid drug
- take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others)
- have 3 or more alcoholic drinks every day while using this product
- take more or for a longer time than directed
Do not use
- if you have ever had an allergic reaction to any other pain reliever/fever reducer
- right before or after heart surgery
Ask a doctor before use if
- stomach bleeding warning applies to you
- you have problems or serious side effects from taking pain relievers or fever reducers
- you have a history of stomach problems, such as heartburn
- you have high blood pressure, heart disease, liver cirrhosis, kidney disease, or asthma
- you are taking a diuretic
Ask a doctor or pharmacist before use if you are
- under a doctor's care for any serious condition
- taking aspirin for heart attack or stroke, because ibuprofen may decrease this benefit of aspirin
- taking any other drug
When using this product
- take with food or milk if stomach upset occurs
- the risk of heart attack or stroke may increase if you use more than directed or for longer than directed
Stop use and ask a doctor if
- side effects occur. You may report side effects to FDA at 1-800-FDA-1088.
- you experience any of the following signs of stomach bleeding:
- feel faint
- vomit blood
- have bloody or black stools
- have stomach pain that does not get better
- pain gets worse or lasts more than 10 days
- fever gets worse or lasts more than 3 days
- redness or swelling is present in the painful area
- any new symptoms appear
OTC - PREGNANCY OR BREAST FEEDING SECTION
If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use ibuprofen during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Directions
- do not take more than directed
- the smallest effective dose should be used
- do not take longer than 10 days, unless directed by a doctor (see Warnings)
| adults and children 12 years and over |
|
| children under 12 years |
|
Other information
- store between 20°-25°C (68°-77°F)
- avoid excessive heat above 40°C (104°F)
- read all warnings and directions before use
- retain carton for complete product information
Inactive ingredients
colloidal silicon dioxide, corn starch, hypromellose, FD&C yellow #6 aluminum lake, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone K30, pregelatinized starch, sodium starch glycolate, stearic acid, talc, titanium dioxide, triacetin
PRINCIPAL DISPLAY PANEL
†Compare to the active ingredient in Motrin® IB
Marc’s®
Ibuprofen
Tablets, 200 mg
Pain Reliever/Fever Reducer (NSAID)
100 Caplets**
**Capsule-Shaped Tablets
Products#
Every source-derived product name is available through these pages.
- Ibuprofen
- SILICON DIOXIDE
- STARCH, CORN
- HYPROMELLOSES
- FD&C YELLOW NO. 6
- ALUMINUM OXIDE
- MAGNESIUM STEARATE
- CELLULOSE, MICROCRYSTALLINE
- POLYDEXTROSE
- POLYETHYLENE GLYCOL, UNSPECIFIED
- POVIDONE K30
- SODIUM STARCH GLYCOLATE TYPE A CORN
- STEARIC ACID
- TALC
- TITANIUM DIOXIDE
- TRIACETIN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68998-112 | 68998-112-03 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091355-001 | IBUPROFEN | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A091355-001 | IBUPROFEN | 200MG | TABLET / ORAL | 2011-04-04 | f41ea6bd6efb… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| bed62c4e-34c3-6e3f-e053-2a95a90a2921 | 224232ca-157f-47ff-bd98-178db900c7dc | 2021-03-31 | Warnings | bed62c4e-34c3-6e3f-e053-2a95a90a2921 224232ca-157f-47ff-bd98-178db900c7dc |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.